Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Jeffrey Summe

Family Medicine Lynnwood, WA Doctor of Osteopathy

NPI 1861409732 CMS profile 130001

19031 33Rd Ave W, Suite 314, Lynnwood, WA 98036

Open in the dashboard

General payments

$14,339

720 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jeffrey Summe of Lynnwood, WA is reported in the CMS Open Payments database as having received $14,339 across 720 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Family Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $400 20
2024 General $511 23
2023 General $1,201 55
2022 General $2,063 85
2021 General $2,760 138
2020 General $2,892 147
2019 General $4,512 252

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jeffrey Summe
  • Family Medicine median
  • Middle half of Family Medicine
  • National median

In program year 2025, general payments to Jeffrey Summe were reported at $400. Among 56,786 Family Medicine profiles paid that year, the median was $155 and the middle half received between $45 and $549.

Show as a table
Year Jeffrey Summe Family Medicine median Middle half National median
2019 $4,512 $150 $41–$543 $163
2020 $2,892 $120 $32–$415 $114
2021 $2,760 $137 $35–$551 $132
2022 $2,063 $137 $37–$512 $149
2023 $1,201 $149 $42–$545 $160
2024 $511 $156 $44–$560 $164
2025 $400 $155 $45–$549 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AstraZeneca Pharmaceuticals LP $2,013 83 payments
  2. Orexo US, Inc. $1,705 104 payments
  3. Novo Nordisk Inc $1,259 58 payments
  4. Salix Pharmaceuticals, a division of Bausch Health US, LLC $1,234 68 payments
  5. Gilead Sciences, Inc. $1,169 43 payments
  6. AbbVie, Inc. $910 34 payments
  7. Zyla Life Sciences $773 58 payments
  8. Janssen Pharmaceuticals, Inc $725 25 payments
  9. Pfizer Inc. $583 29 payments
  10. Teva Pharmaceuticals USA, Inc. $438 45 payments
  11. Other $3,531 173 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $14,287 712 payments
  2. Education $52 8 payments
Products named General payments · program years 2019–2025
  1. Zubsolv $1,571 93 payments
  2. FARXIGA $1,054 43 payments
  3. SPRIX $703 50 payments
  4. Saxenda $598 29 payments
  5. XARELTO $533 23 payments
  6. BREZTRI $525 18 payments
  7. XIFAXAN $460 25 payments
  8. UBRELVY $458 19 payments
  9. TRULANCE $419 26 payments
  10. INVOKANA $392 11 payments
  11. Other $8,233 422 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 15 drugs

Part D claims

322

Median for Family Practice: 1,826

Drug cost

$20,797

Median for Family Practice: $120,094

Branded share of claims

54%

Median for Family Practice: 18.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Suboxone Buprenorphine Hcl/Naloxone Hcl Brand 15 $9,730
Buprenorphine-Naloxone Buprenorphine Hcl/Naloxone Hcl Brand 36 $6,706
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 72 $1,967
Omeprazole Generic 19 $415
Lisinopril-Hydrochlorothiazide Lisinopril/Hydrochlorothiazide Brand 20 $293
Butalbital-Acetaminophen-Caffe Butalb/Acetaminophen/Caffeine Brand 14 $265
Ondansetron Odt Ondansetron Brand 17 $252
Hydroxychloroquine Sulfate Generic 12 $242
Buprenorphine Hcl Generic 17 $217
Amlodipine Besylate Generic 20 $208

The 10 drugs with the highest cost, of 15 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 105,120 Part D prescribers listed as Family Practice; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 8 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Zubsolv
$231 — —
FARXIGA
$57 — —
UBRELVY
$49 — —
QULIPTA
$49 — —
XIFAXAN
$36 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 8 in the dashboard with a free account

Records

720 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Family Medicine in Washington

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record